Outlook Therapeutics, Inc. — Director's Dealing 2021

Dec 23, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Outlook Therapeutics, Inc. (OTLK)
CIK: 0001649989
Period of Report: 2021-12-21

Reporting Person: Dagnon Terry (Chief Operating Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-12-21	Stock Option (Right to Buy)	$1.44	A	800000	Acquired	2031-12-21	Common Stock (800000)	Direct

Footnotes

F1: 25% of the shares subject to the option shall vest on December 21, 2022, with the remaining shares vesting in equal monthly installments over the following three years thereafter, subject to the Reporting Person's continuous service with the Issuer on each such date. The option is also subject to acceleration under certain circumstances.